Project Details
Nuclear receptors as regulators of tissue responses and potential targets for anti-fibrotic therapies
Applicant
Professor Dr. Jörg Hans Wilhelm Distler
Subject Area
Rheumatology
Term
from 2014 to 2021
Project identifier
Deutsche Forschungsgemeinschaft (DFG) - Project number 258918299
Final Report Year
2020
Final Report Abstract
No abstract available
Publications
-
Hippocampal structure and function are maintained despite severe innate peripheral inflammation. Brain, Behavior, and Immunity, Vol. 49. 2015, pp. 156-170.
Süß P., Kalinichenko L., Baum W., Reichel M., Kornhuber J., Loskarn S., Ettle B., Distler J.H., Schett G., Winkler J., Müller C.P., Schlachetzki J.C.
-
Increased plasma soluble urokinase plasminogen activator receptor levels in systemic sclerosis: possible association with microvascular abnormalities and extent of fibrosis. Clinical Chemistry and Laboratory Medicine (CCLM), Band 53. 2015, Heft 11, S. 1799-1805.
Legány N., Toldi G., Distler J.H., Beyer C., Szalay B., Kovács L., Vásárhelyi B., Balog A.
-
Inhibition of Notch1 promotes hedgehog signalling in a HES1-dependent manner in chondrocytes and exacerbates experimental osteoarthritis. Annals of the Rheumatic Diseases, Vol. 75. 2016, Issue 11, pp. 2037-2044.
Lin N.Y., Distler A., Beyer C., Philipi-Schöbinger A., Breda S., Dees C., Stock M., Tomcik M., Niemeier A., Dell'Accio F., Gelse K., Mattson M.P., Schett G., Distler J.H.
-
N-terminal pro-brain natriuretic peptide is a strong predictor of mortality in systemic sclerosis. International Journal of Cardiology, Vol. 223. 2016, pp. 385-389.
Allanore Y-, Komocsi A-, Vettori S-, Hachulla E-, Hunzelmann N-, Distler J-, Avouac J-, Gobeaux C-, Launay D-, Czirjak L-, Kahan A-, Meune C.
-
Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™). Clinical and Experimental Rheumatology, Vol. 35. 2017, Suppl. 106, pp. S75-S81.
Distler O., Brown K.K., Distler J.H.W., Assassi S., Maher T.M., Cottin V, Varga J., Coeck C., Gahlemann M., Sauter W., Schmidt H., Highland K.B., SENSCIS™ trial investigators
-
Targeting of NADPH oxidase in vitro and in vivo suppresses fibroblast activation and experimental skin fibrosis. Experimental Dermatology, Vol.26. 2017, Issue 1, pp. 73-81.
Dosoki H., Stegemann A., Taha M., Schnittler H., Luger T.A., Schröder K., Distler J.H., Kerkhoff C., Böhm M.
-
Autoantibodies Recognizing Secondary NEcrotic Cells Promote Neutrophilic Phagocytosis and Identify Patients With Systemic Lupus Erythematosus.
Frontiers in Immunology, Vol. 9. 2018: 989.
Biermann M.H.C., Boeltz S., Pieterse E., Knopf J., Rech J., Bilyy R., van der Vlag J., Tincani A., Distler J.H.W., Krönke G., Schett G.A., Herrmann M., Muñoz L.E.
-
NR4A1 regulates motility of osteoclast precursors and serves as target for the modulation of systemic bone turnover. Journal of Bone and Mineral Research, Vol. 33. 2018, Issue 11 pp. 2035-2047.
Scholtysek C., Ipseiz N., Böhm C., Krishnacoumar B., Stenzel M., Czerwinski T., Weidner D., Klej A., Stoll C., Distler J., et al.
-
Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study. Journal of Rheumatology, Vol. 45. 2018, Issue 3, pp. 405-410.
Hsu V.M., Denton C.P., Domsic R.T., Furst D.E., Rischmueller M., Stanislav M., Steen V.D., Distler J.H.W., Korish S., Cooper A., Choi S., Schafer P.H., Horan G., Hough D.R.
-
GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways. Nature Communications, Vol. 10. 2019, Issue 1, Article number: 4955.
López-Isac E., Acosta-Herrera M., Distler J.H.W., Martin J., et al.
-
Vascularised human skin equivalents as a novel in vitro model of skin fibrosis and platform for testing of antifibrotic drugs. Annals of the Rheumatic Diseases, Vol. 78. 2019, Issue 12, pp. 1686-1692.
Matei A.E., Chen C.W., Kiesewetter L., Györfi A.H., Li Y.N., Distler J.H.W., et al.